Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "cancer gene therapy" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
    Autorzy:
    Jazowiecka-Rakus, Joanna
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1041570.pdf
    Data publikacji:
    2004
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    cancer gene therapy
    tumour targeting
    cytosine deaminase
    Salmonella
    Opis:
    A tumour therapy is proposed based on attenuated Salmonella typhimurium VNP20047 expressing the Escherichia coli cytosine deaminase gene. VNP20047 was administered intravenously to B16(F10) melanoma-bearing C57BL/6 mice. VNP20047 proliferated within tumours and livers regardless of the initial inoculum dose. After 10 days the number of bacteria increased in livers up to 4.2 × 106 cfu/g and decreased in tumours down to 5.9 × 106 cfu/g. VNP20047 at 1 × 105 cfu/mouse, when combined with 5-fluorocytosine, inhibited tumour growth by 85% without prolonging animal survival. Histology studies revealed severe lesions in tumours and livers. These data suggest that S. typhimurium VNP20047 induced inflammatory responses, even though the strain was attenuated.
    Źródło:
    Acta Biochimica Polonica; 2004, 51, 3; 851-856
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The role of cell adhesion molecule in cancer progression and its application in cancer therapy.
    Autorzy:
    Okegawa, Takatsugu
    Pong, Rey-Chen
    Li, Yingming
    Hsieh, Jer-Tsong
    Powiązania:
    https://bibliotekanauki.pl/articles/1043281.pdf
    Data publikacji:
    2004
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    cancer gene therapy
    gene
    cell adhesion molecules
    tumor progression
    tumor suppressor
    Opis:
    Multiple and diverse cell adhesion molecules take part in intercellular and cell-extracellular matrix interactions of cancer. Cancer progression is a multi-step process in which some adhesion molecules play a pivotal role in the development of recurrent, invasive, and distant metastasis. A growing body of evidence indicates that alterations in the adhesion properties of neoplastic cells play a pivotal role in the development and progression of cancer. Loss of intercellular adhesion and the desquamation of cells from the underlying lamina propria allows malignant cells to escape from their site of origin, degrade the extracellular matrix, acquire a more motile and invasion phenotype, and finally, invade and metastasize. In addition to participating in tumor invasiveness and metastasis, adhesion molecules regulate or significantly contribute to a variety of functions including signal transduction, cell growth, differentiation, site-specific gene expression, morphogenesis, immunologic function, cell motility, wound healing, and inflammation. Cell adhesion molecule (CAM), a diverse system of transmembrane glycoproteins has been identified that mediates the cell-cell and cell-extracellular matrix adhesion and also serves as the receptor for different kinds of virus. We summarize recent progress regarding the role of CAM, particularly, immunoglobulin-CAMs and cadherins in the progression of cancer and discuss the potential application of CAMs in the development of cancer therapy mainly on urogenital cancer.
    Źródło:
    Acta Biochimica Polonica; 2004, 51, 2; 445-457
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cancer immunotherapy using cells modified with cytokine genes.
    Autorzy:
    Kowalczyk, Dariusz
    Wysocki, Piotr
    Mackiewicz, Andrzej
    Powiązania:
    https://bibliotekanauki.pl/articles/1043434.pdf
    Data publikacji:
    2003
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    cancer
    cancer vaccines
    cytokines
    dendritic cells
    gene therapy
    Opis:
    The ability of various cytokines to hamper tumor growth or to induce anti-tumor immune response has resulted in their study as antitumor agents in gene therapy approaches. In this review we will concentrate on the costimulation of antitumor immune responses using modification of various cell types by cytokine genes. Several strategies have emerged such as (i) modification of tumor cells with cytokine genes ex vivo (whole tumor cell vaccines), (ii) ex vivo modification of other cell types for cytokine gene delivery, (iii) delivery of cytokine genes into tumor microenvironment in vivo, (iv) modification of dendritic cells with cytokine genes ex vivo. Originally single cytokine genes were used. Subsequently, multiple cytokine genes were applied simultaneously, or in combination with other factors such as chemokines, membrane bound co-stimulatory molecules, or tumor associated antigens. In this review we discuss these strategies and their use in cancer treatment as well as the promises and limitations of cytokine based cancer gene therapy. Clinical trials, including our own experience, employing the above strategies are discussed.
    Źródło:
    Acta Biochimica Polonica; 2003, 50, 3; 613-624
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Expression of genes modulated by epigallocatechin-3-gallate in breast cancer cells
    Autorzy:
    Bogacz, A.
    Wolek, M.
    Juskowiak, B.
    Karasiewicz, M.
    Kaminski, A.
    Uzar, I.
    Polaszewska, A.
    Kostrzewa, Z.
    Czerny, B.
    Powiązania:
    https://bibliotekanauki.pl/articles/72469.pdf
    Data publikacji:
    2018
    Wydawca:
    Instytut Włókien Naturalnych i Roślin Zielarskich
    Tematy:
    gene expression
    epigallocatechin-3-gallate
    breast cancer
    cancer cell
    therapy
    Opis:
    Breast cancer is the most common malignant cancer among women. Both drug resistance and metastasis are major problems in the treatment of breast cancer. Therefore, adjuvant therapy may improve patients’ survival and affect their quality of life. It is suggested that epigallocatechin gallate (EGCG) which is well known for its chemopreventive activity and acts on numerous molecular targets may inhibit the growth and metastasis of some cancers. Hence, discovering the metastatic molecular mechanisms for breast cancer may be useful for therapy.The aim of the study was to determine the effect of EGGC on the mRNA expression level of genes such as ZEB1, ABCB1, MDM2, TWIST1 and PTEN in MCF-7 breast cancer cells. MCF7/DOX were cultured in the presence of 0.2 μM DOX and EGCG (20-50 μM). The mRNA expression level was determined by real-time quantitative PCR using RealTime ready Custom Panel 96 kit. Our results showed an important increase (about 2-fold for 20 μM EGCG + 0.2 μM DOX and 2.5-fold for 50 μM EGCG + 0.2 μM DOX, p<0.05) in ZEB1 expression levels. In case of ABCB1 gene lack of influence on the mRNA level was observed (p>0.05). We also observed significant decrease of ZEB1 expression in MCF7 cells with 20 μM and 50 μM EGCG (p<0.05). In addition, EGCG (20 μM) caused an increase of MDM2 and PTEN mRNA levels in almost 100% (p<0.05) and 40% (p>0.05), respectively. Lack of the influence of EGCG was noted for the TWIST1 gene expression. In case of MCF7/DOX we showed an increase of mRNA level of PTEN gene about 50% (p<0.05). These results suggest that EGCG may be potentially used in adjuvant therapy in the breast cancer treatment.
    Źródło:
    Herba Polonica; 2018, 64, 3
    0018-0599
    Pojawia się w:
    Herba Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    DNA microarrays - future in oncology research and therapy
    Autorzy:
    Krol, M.
    Pawlowski, K.M.
    Otrebska, D.
    Motyl, T.
    Powiązania:
    https://bibliotekanauki.pl/articles/3349.pdf
    Data publikacji:
    2008
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    DNA microarray
    future
    oncology
    research
    therapy
    genomics
    gene expression
    canine mammary cancer
    tumour
    human disease
    cancer
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2008, 02, 2
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
    Autorzy:
    Bargiel, J.B.
    Cabaj, J.
    Chmielewska, I.
    Milanowski, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/2098542.pdf
    Data publikacji:
    2021
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    non-small cell lung cancer
    crizotinib
    therapy
    gene rearrangement
    tyrosine kinase inhibitor
    patient
    Opis:
    Introduction. Currently, nearly 23,000 cases of lung cancer are diagnosed in Poland annually, of which 5% are cases with rearrangements in the ALK gene. In recent years, tremendous progress has been made in understanding the genetic makeup of this type of cancer, which has enabled the use of new therapies, in particular, molecularly targeted drugs. Crizotinib is the first oral small molecule inhibitor of ALK, MET and ROS1 receptor tyrosine Kinases approved by the European Medicines Agency(EMA). Case report. The paper presents the case of a 62-year-old patient diagnosed with non-small cell lung cancer with rearrangement in the ALK gene in stage IV of the disease. The patient was qualified for treatment with crizotinib under the B6 drug programme. Treatment started in May 2019. During treatment, assessment was made at 3 control points, where the first and second showed a partial response according to the RECIST 1.1 scale; in the next assessment, the response was maintained in the form of disease stabilization.
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2021, 15, 3; 151-154
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparaty siRNA w terapii genowej raka jajnika
    siRNA preparations in gene therapy of ovarian cancer
    Autorzy:
    Pankowska, Magdalena
    Stachurska, Anna
    Woźniak, Małgorzata
    Małecki, Maciej
    Powiązania:
    https://bibliotekanauki.pl/articles/1031566.pdf
    Data publikacji:
    2014
    Wydawca:
    Medical Communications
    Tematy:
    sirna
    rak jajnika
    terapia genowa
    badania kliniczne
    chemiooporność
    ovarian cancer
    gene therapy
    clinical research
    chemoresistance
    Opis:
    According to statistics, ovarian cancer is the fourth cause of death due to gynecologic cancer. It results from late diagnosis of the disease, caused by the lack of characteristic symptoms, as well as from unsatisfactory treatment methods due to e.g. cell resistance to chemotherapy. The search for new therapies is still in progress. It is believed that preparations whose activity is based on RNA interference, i.e. gene silencing with the use of siRNA, are a promising group of new antineoplastic medications. Fire et al. were awarded the Nobel Prize for discovering this phenomenon. The phenomenon of siRNA interference in healthy cells is a natural protective mechanism. Genes are silenced in the cytoplasm with the use of the Dicer enzyme. siRNA gene preparations are delivered into cells with the use of viral methods such as AAV or adenoviruses, as well as non-viral methods e.g. with the use of liposomes. Clinical trials concerning siRNA preparations are now in the first phase. They are conducted on two gene preparations: CALAA-01 and siRNA nanomolecule directed against PLK1. In this paper attention was drawn to the therapeutic meaning of siRNA sequences in relation to the following genes: MDR1, VEGF, MMP, CD44, HER2, SHH, STAT. Both experimental and clinical studies give hope for the use of the described mechanisms in fight with ovarian cancer in the future.
    Rak jajnika według statystyk zajmuje czwarte miejsce wśród zgonów z powodu nowotworów ginekologicznych. Wynika to zarówno z późnego rozpoznania choroby, spowodowanego brakiem charakterystycznych objawów, jak i stale niezadowalających efektów leczenia, m.in. ze względu na oporność komórek na chemioterapię. Poszukiwanie nowych metod terapii jest więc nadal aktualne. Uważa się, że obiecującą grupą potencjalnych leków przeciwnowotworowych mogą być preparaty, których aktywność opiera się na zjawisku interferencji RNA, czyli wyciszaniu genów za pomocą siRNA. Za odkrycie tego zjawiska Fire i wsp. zostali uhonorowani Nagrodą Nobla. Zjawisko interferencji siRNA w prawidłowych komórkach jest naturalnym mechanizmem obronnym. Do wyciszenia genów dochodzi w cytoplazmie przy udziale enzymu Dicer. Preparaty genowe siRNA wprowadza się do komórek, wykorzystując metody wirusowe, takie jak AAV czy adenowirusy, a także za pomocą metod niewirusowych, np. z zastosowaniem liposomów. Badania kliniczne preparatów genowych siRNA znajdują się obecnie w pierwszej fazie. Prowadzone są na dwóch preparatach genowych CALAA-01 oraz na nanocząsteczce siRNA skierowanej przeciw PLK1. W niniejszej pracy skupiono uwagę na terapeutycznym znaczeniu sekwencji siRNA w stosunku do genów: MDR1, VEGF, MMP, CD44, HER2, SHH, STAT. Zarówno badania eksperymentalne, jak i kliniczne niosą nadzieję na wykorzystanie w przyszłości omawianego mechanizmu do walki z rakiem jajnika.
    Źródło:
    Current Gynecologic Oncology; 2014, 12, 3; 197-205
    2451-0750
    Pojawia się w:
    Current Gynecologic Oncology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Search for mouse gene related to GA733 human tumor antigen gene
    Autorzy:
    Zielewicz, J
    Skrzypczak, M.
    Wojcierowski, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/2048195.pdf
    Data publikacji:
    1995
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    human antigen
    glycoprotein
    human genetics
    mice
    gene sequence
    adenocarcinoma
    cancer therapy
    electrophoresis
    carcinoma cell
    bacteriophage
    antigen
    gene
    mouse
    oncoantigen
    hybridization
    tumour etiology
    tumour
    DNA
    Opis:
    Human antigen GA733-1, defined as 40 kDa cell glycoprotein, is one of the antigens associated with gastrointestinal carcinomas. Its studies may contribute to the tumor etiology and therapy effects in animal model.
    Źródło:
    Journal of Applied Genetics; 1995, 36, 3; 273-277
    1234-1983
    Pojawia się w:
    Journal of Applied Genetics
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies